This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Abifadel M., Varret M., Rabès J.P., Allard D., Ouguerram K., Devillers M., Cruaud C., Benjannet S., Wickham L., Erlich D., Derré A., Villéger L., Farnier M., Beucler I., Bruckert E. i wsp.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet., 2003; 34: 154–156AbifadelM.VarretM.RabèsJ.P.AllardD.OuguerramK.DevillersM.CruaudC.BenjannetS.WickhamL.ErlichD.DerréA.VillégerL.FarnierM.BeuclerI.BruckertE.i wsp.Mutations in PCSK9 cause autosomal dominant hypercholesterolemia20033415415610.1038/ng116112730697Search in Google Scholar
Adorni M.P., Cipollari E., Favari E., Zanotti I., Zimetti F., Corsini A., Ricci C., Bernini F., Ferri N.: Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages. Atherosclerosis, 2017; 256: 1–6AdorniM.P.CipollariE.FavariE.ZanottiI.ZimettiF.CorsiniA.RicciC.BerniniF.FerriN.Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages20172561610.1016/j.atherosclerosis.2016.11.01927940374Search in Google Scholar
An D., Wei X., Li H., Gu H., Huang T., Zhao G., Liu B., Wang W., Chen L., Ma W., Zhang H., Cao S., Yuan Z.: Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics. Sci. Rep., 2015; 5: 17559AnD.WeiX.LiH.GuH.HuangT.ZhaoG.LiuB.WangW.ChenL.MaW.ZhangH.CaoS.YuanZ.Identification of PCSK9 as a novel serum biomarker for the prenatal diagnosis of neural tube defects using iTRAQ quantitative proteomics201551755910.1038/srep17559468691326691006Search in Google Scholar
Arama C., Diarra I., Kouriba B., Sirois F., Fedoryak O., Thera M.A., Coulibaly D., Lyke K.E., Plowe C.V., Chrétien M., Doumbo O.K., Mbikay M.: Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. PLoS One, 2018; 13: e0192850AramaC.DiarraI.KouribaB.SiroisF.FedoryakO.TheraM.A.CoulibalyD.LykeK.E.PloweC.V.ChrétienM.DoumboO.K.MbikayM.Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children201813e019285010.1371/journal.pone.0192850581395529447211Search in Google Scholar
Bai X.Q., Peng J., Wang M.M., Xiao J., Xiang Q., Ren Z., Wen H.Y., Jiang Z.S., Tang Z.H., Liu L.S.: PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis? Clin. Chim. Acta, 2018; 483: 192–196BaiX.Q.PengJ.WangM.M.XiaoJ.XiangQ.RenZ.WenH.Y.JiangZ.S.TangZ.H.LiuL.S.PCSK9: A potential regulator of apoE/apoER2 against inflammation in atherosclerosis?201848319219610.1016/j.cca.2018.04.04029727700Search in Google Scholar
Banach M., Rizzo M., Nikolic D., Howard G., Howard V.J., Mikhailidis D.P.: Intensive LDL-cholesterol lowering therapy and neurocognitive function. Pharmacol. Ther., 2017; 170: 181–191BanachM.RizzoM.NikolicD.HowardG.HowardV.J.MikhailidisD.P.Intensive LDL-cholesterol lowering therapy and neurocognitive function201717018119110.1016/j.pharmthera.2016.11.00127865998Search in Google Scholar
Barale C., Bonomo K., Frascaroli C., Morotti A., Guerrasio A., Cavalot F., Russo I.: Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. Nutr. Metab. Cardiovasc. Dis., 2020; 30: 282–291BaraleC.BonomoK.FrascaroliC.MorottiA.GuerrasioA.CavalotF.RussoI.Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up20203028229110.1016/j.numecd.2019.09.01231653513Search in Google Scholar
Berger J.M., Vaillant N., Le May C., Calderon C., Brégeon J., Prieur X., Hadchouel J., Loirand G., Cariou B.: PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension. Atherosclerosis, 2015; 239: 252–259BergerJ.M.VaillantN.Le MayC.CalderonC.BrégeonJ.PrieurX.HadchouelJ.LoirandG.CariouB.PCSK9-deficiency does not alter blood pressure and sodium balance in mouse models of hypertension201523925225910.1016/j.atherosclerosis.2015.01.01225621930Search in Google Scholar
Besseling J., Kastelein J.J., Defesche J.C., Hutten B.A., Hovingh G.K.: Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA, 2015; 313: 1029–1036BesselingJ.KasteleinJ.J.DefescheJ.C.HuttenB.A.HovinghG.K.Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus20153131029103610.1001/jama.2015.120625756439Search in Google Scholar
Blom D.J., Djedjos C.S., Monsalvo M.L., Bridges I., Wasserman S.M., Scott R., Roth E.: Effects of evolocumab on vitamin E and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study. Circ. Res., 2015; 117: 731–741BlomD.J.DjedjosC.S.MonsalvoM.L.BridgesI.WassermanS.M.ScottR.RothE.Effects of evolocumab on vitamin E and steroid hormone levels: Results from the 52-week, phase 3, double-blind, randomized, placebo-controlled DESCARTES study201511773174110.1161/CIRCRESAHA.115.30707126228031Search in Google Scholar
Blom D.J., Hala T., Bolognese M., Lillestol M.J., Toth P.D., Burgess L., Ceska R., Roth E., Koren M.J., Ballantyne C.M., Monsalvo M.L., Tsirtsonis K., Kim J.B., Scott R., Wasserman S.M.: A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med., 2014; 370: 1809–1819BlomD.J.HalaT.BologneseM.LillestolM.J.TothP.D.BurgessL.CeskaR.RothE.KorenM.J.BallantyneC.M.MonsalvoM.L.TsirtsonisK.KimJ.B.ScottR.WassermanS.M.A 52-week placebo-controlled trial of evolocumab in hyperlipidemia20143701809181910.1056/NEJMoa1316222Search in Google Scholar
Boyd J.H., Fjell C.D., Russell J.A., Sirounis D., Cirstea M.S., Walley K.R.: Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis. J. Innate Immun., 2016; 8: 211–220BoydJ.H.FjellC.D.RussellJ.A.SirounisD.CirsteaM.S.WalleyK.R.Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis2016821122010.1159/000442976Search in Google Scholar
Bułdak Ł., Marek B., Kajdaniuk D., Urbanek A., Janyga S., Bołdys A., Basiak M., Maligłówka M., Okopień B.: Endocrine diseases as causes of secondary hyperlipidemia. Endokrynol. Pol., 2019; 70: 511–519BułdakŁ.MarekB.KajdaniukD.UrbanekA.JanygaS.BołdysA.BasiakM.MaligłówkaM.OkopieńB.Endocrine diseases as causes of secondary hyperlipidemia20197051151910.5603/EP.a2019.0041Search in Google Scholar
Campbell J.H., Popadynec L., Nestel P.J., Campbell G.R.: Lipid accumulation in arterial smooth muscle cells. Influence of phenotype. Atherosclerosis, 1983; 47: 279–295CampbellJ.H.PopadynecL.NestelP.J.CampbellG.R.Lipid accumulation in arterial smooth muscle cells. Influence of phenotype19834727929510.1016/0021-9150(83)90059-XSearch in Google Scholar
Cariou B., Benoit I., Le May C.: Preserved adrenal function in fully PCSK9-deficient subject. Int. J. Cardiol., 2014; 176: 499–500CariouB.BenoitI.Le MayC.Preserved adrenal function in fully PCSK9-deficient subject201417649950010.1016/j.ijcard.2014.07.05725062564Search in Google Scholar
Cederberg H., Stančáková A., Yaluri N., Modi S., Kuusisto J., Laakso M.: Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6-year follow-up study of the METSIM cohort. Diabetologia, 2015; 58: 1109–1117CederbergH.StančákováA.YaluriN.ModiS.KuusistoJ.LaaksoM.Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: A 6-year follow-up study of the METSIM cohort2015581109111710.1007/s00125-015-3528-525754552Search in Google Scholar
Chang T.J., Chiu Y.F., Sheu W.H., Shih K.C., Hwu C.M., Quertermous T., Jou Y.S., Kuo S.S., Chang Y.C., Chuang L.M.: Genetic polymorphisms of PCSK2 are associated with glucose homeostasis and progression to type 2 diabetes in a Chinese population. Sci. Rep., 2015; 5: 14380ChangT.J.ChiuY.F.SheuW.H.ShihK.C.HwuC.M.QuertermousT.JouY.S.KuoS.S.ChangY.C.ChuangL.M.Genetic polymorphisms of PCSK2 are associated with glucose homeostasis and progression to type 2 diabetes in a Chinese population201551438010.1038/srep14380466038426607656Search in Google Scholar
Chen S., Cao P., Dong N., Peng J., Zhang C., Wang H., Zhou T., Yang J., Zhang Y., Martelli E.E., Naga Prasad S.V., Miller R.E., Malfait A.M., Zhou Y., Wu Q.: PCSK6-mediated corin activation is essential for normal blood pressure. Nat. Med., 2015; 21: 1048–1053ChenS.CaoP.DongN.PengJ.ZhangC.WangH.ZhouT.YangJ.ZhangY.MartelliE.E.Naga PrasadS.V.MillerR.E.MalfaitA.M.ZhouY.WuQ.PCSK6-mediated corin activation is essential for normal blood pressure2015211048105310.1038/nm.3920471051726259032Search in Google Scholar
Cheng J.M., Oemrawsingh R.M., Garcia-Garcia H.M., Boersma E., van Geuns R.J., Serruys P.W., Kardys I., Akkerhuis K.M.: PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMOIVUS study. Atherosclerosis, 2016; 248: 117–122ChengJ.M.OemrawsinghR.M.Garcia-GarciaH.M.BoersmaE.van GeunsR.J.SerruysP.W.KardysI.AkkerhuisK.M.PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMOIVUS study201624811712210.1016/j.atherosclerosis.2016.03.01027015246Search in Google Scholar
Cohen J.C., Boerwinkle E., Mosley T.H. Jr, Hobbs H.H.: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med., 2006; 354: 1264–1272CohenJ.C.BoerwinkleE.MosleyT.H.JrHobbsH.H.Sequence variations in PCSK9, low LDL, and protection against coronary heart disease20063541264127210.1056/NEJMoa05401316554528Search in Google Scholar
D’Ardes D., Santilli F., Guagnano M.T., Bucci M., Cipollone F.: From endothelium to lipids, through microRNAs and PCSK9: A fascinating travel across atherosclerosis. High Blood Press. Cardiovasc. Prev., 2020; 27: 1–8D’ArdesD.SantilliF.GuagnanoM.T.BucciM.CipolloneF.From endothelium to lipids, through microRNAs and PCSK9: A fascinating travel across atherosclerosis. High Blood Press20202718Search in Google Scholar
de Carvahlo L.S., Campos A.M., Sposito A.C.: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: A systematic review and meta-analysis with over 96,000 patient-years. Diabetes Care, 2018; 41: 364–367de CarvahloL.S.CamposA.M.SpositoA.C.Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: A systematic review and meta-analysis with over 96,000 patient-years20184136436710.2337/dc17-146429180351Search in Google Scholar
Denis M., Marcinkiewicz J., Zaid A., Gauthier D., Poirier S., Lazure C., Seidah N.G., Prat A.: Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation, 2012; 125: 894–901DenisM.MarcinkiewiczJ.ZaidA.GauthierD.PoirierS.LazureC.SeidahN.G.PratA.Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice201212589490110.1161/CIRCULATIONAHA.111.05740622261195Search in Google Scholar
Diedrich G.: How does hepatitis C virus enter cells? FEBS J., 2006; 273: 3871–3885DiedrichG.How does hepatitis C virus enter cells?20062733871388510.1111/j.1742-4658.2006.05379.x16934030Search in Google Scholar
Ding Z., Liu S., Wang X., Deng X., Fan Y., Shahanawaz J., Shmookler Reis R.J., Varughese K.I., Sawamura T., Mehta J.L.: Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc. Res., 2015; 107: 556–567DingZ.LiuS.WangX.DengX.FanY.ShahanawazJ.Shmookler ReisR.J.VarugheseK.I.SawamuraT.MehtaJ.L.Cross-talk between LOX-1 and PCSK9 in vascular tissues201510755656710.1093/cvr/cvv17826092101Search in Google Scholar
Ding Z., Liu S., Wang X., Theus S., Deng X., Fan Y., Zhou S., Mehta J.L.: PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages. Cardiovasc. Res., 2018; 114: 1145–1153DingZ.LiuS.WangX.TheusS.DengX.FanY.ZhouS.MehtaJ.L.PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages20181141145115310.1093/cvr/cvy07929617722Search in Google Scholar
Dyrbuś K., Gąsior M., Penson P., Ray K.K., Banach M.: Inclisiran – New hope in the management of lipid disorders? J. Clin. Lipidol., 2020; 14: 16–27DyrbuśK.GąsiorM.PensonP.RayK.K.BanachM.Inclisiran – New hope in the management of lipid disorders?202014162710.1016/j.jacl.2019.11.00131879073Search in Google Scholar
Feingold K.R., Moser A.H., Shigenaga J.K., Patzek S.M., Grunfeld C.: Inflammation stimulates the expression of PCSK9. Biochem. Biophys. Res. Commun., 2008; 374: 341–344FeingoldK.R.MoserA.H.ShigenagaJ.K.PatzekS.M.GrunfeldC.Inflammation stimulates the expression of PCSK9200837434134410.1016/j.bbrc.2008.07.023257108118638454Search in Google Scholar
Ferri N., Tibolla G., Pirillo A., Cipollone F., Mezzetti A., Pacia S., Corsini A., Catapano A.L.: Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis, 2012; 220: 381–386FerriN.TibollaG.PirilloA.CipolloneF.MezzettiA.PaciaS.CorsiniA.CatapanoA.L.Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels201222038138610.1016/j.atherosclerosis.2011.11.02622176652Search in Google Scholar
Gencer B., Kronenberg F., Stroes E.S., Mach F.: Lipoprotein(a): The revenant. Eur. Heart J., 2017; 38: 1553–1560GencerB.KronenbergF.StroesE.S.MachF.Lipoprotein(a): The revenant2017381553156010.1093/eurheartj/ehx03328329241Search in Google Scholar
Gencer B., Mach F., Guo J., Im K., Ruzza A., Wang H., Kurtz C.E., Pedersen T.R., Keech A.C., Ott B.R., Sabatine M.S., Giugliano R.P., FOURIER Investigators: Cognition after lowering LDL-cholesterol with evolocumab. J. Am. Coll. Cardiol., 2020; 75: 2283–2293GencerB.MachF.GuoJ.ImK.RuzzaA.WangH.KurtzC.E.PedersenT.R.KeechA.C.OttB.R.SabatineM.S.GiuglianoR.P.FOURIER InvestigatorsCognition after lowering LDL-cholesterol with evolocumab2020752283229310.1016/j.jacc.2020.03.03932381158Search in Google Scholar
Geovanini G.R., Libby P.: Atherosclerosis and inflammation: Overview and updates. Clin. Sci., 2018; 132: 1243–1252GeovaniniG.R.LibbyP.Atherosclerosis and inflammation: Overview and updates20181321243125210.1042/CS20180306Search in Google Scholar
German C.A., Shapiro M.D.: Small interfering RNA therapeutic inclisiran: A new approach to targeting PCSK9. BioDrugs, 2020; 34: 1–9GermanC.A.ShapiroM.D.Small interfering RNA therapeutic inclisiran: A new approach to targeting PCSK92020341910.1007/s40259-019-00399-6Search in Google Scholar
Giugliano R.P., Desai N.R., Kohli P., Rogers W.J., Somaratne R., Huang F., Liu T., Mohanavelu S., Hoffman E.B., McDonald S.T., Abrahamsen T.E., Wasserman S.M., Scott R., Sabatine M.S., LAPLACE-TIMI 57 Investigators: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet, 2012; 380: 2007–2017GiuglianoR.P.DesaiN.R.KohliP.RogersW.J.SomaratneR.HuangF.LiuT.MohanaveluS.HoffmanE.B.McDonaldS.T.AbrahamsenT.E.WassermanS.M.ScottR.SabatineM.S.LAPLACE-TIMI 57 InvestigatorsEfficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study20123802007201710.1016/S0140-6736(12)61770-XSearch in Google Scholar
Giugliano R.P., Pedersen T.R., Saver J.L., Sever P.S., Keech A.C., Bohula E.A., Murphy S.A., Wasserman S.M., Honarpour N., Wang H., Pineda A.L., Sabatine M.S., FOURIER Investigators: Stroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis. Stroke, 2020; 51: 1546–1554GiuglianoR.P.PedersenT.R.SaverJ.L.SeverP.S.KeechA.C.BohulaE.A.MurphyS.A.WassermanS.M.HonarpourN.WangH.PinedaA.L.SabatineM.S.FOURIER InvestigatorsStroke prevention with the PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitor evolocumab added to statin in high-risk patients with stable atherosclerosis2020511546155410.1161/STROKEAHA.119.02775932312223Search in Google Scholar
Guillemot J., Essalmani R., Hamelin J., Seidah N.G.: Is there a link between proprotein convertase PC7 activity and human lipid homeostasis? FEBS Open Bio, 2014; 4: 741–745GuillemotJ.EssalmaniR.HamelinJ.SeidahN.G.Is there a link between proprotein convertase PC7 activity and human lipid homeostasis?2014474174510.1016/j.fob.2014.08.004420809325349778Search in Google Scholar
Haas M.E., Levenson A.E., Sun X., Liao W.H., Rutkowski J.M., de Ferranti S.D., Schumacher V.A., Scherer P.E., Salant D.J., Biddinger S.B.: The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation, 2016; 134: 61–72HaasM.E.LevensonA.E.SunX.LiaoW.H.RutkowskiJ.M.de FerrantiS.D.SchumacherV.A.SchererP.E.SalantD.J.BiddingerS.B.The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia2016134617210.1161/CIRCULATIONAHA.115.020912534585327358438Search in Google Scholar
Hoac B., Susan-Resiga D., Essalmani R., Marcinkiweicz E., Seidah N.G., McKee M.D.: Osteopontin as a novel substrate for the proprotein convertase 5/6 (PCSK5) in bone. Bone, 2018; 107: 45–55HoacB.Susan-ResigaD.EssalmaniR.MarcinkiweiczE.SeidahN.G.McKeeM.D.Osteopontin as a novel substrate for the proprotein convertase 5/6 (PCSK5) in bone2018107455510.1016/j.bone.2017.11.00229126984Search in Google Scholar
Hu J., Zhang Z., Shen W.J., Azhar S.: Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr. Metab., 2010; 7: 47HuJ.ZhangZ.ShenW.J.AzharS.Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones201074710.1186/1743-7075-7-47289069720515451Search in Google Scholar
Izaguirre G.: The proteolytic regulation of virus cell entry by furin and other proprotein convertases. Viruses, 2019; 11: 837IzaguirreG.The proteolytic regulation of virus cell entry by furin and other proprotein convertases20191183710.3390/v11090837678429331505793Search in Google Scholar
Karagiannis A.D., Liu M., Toth P.P., Zhao S., Agrawal D.K., Libby P., Chatzizisis Y.S.: Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation. Curr. Atheroscler. Rep., 2018; 20: 20KaragiannisA.D.LiuM.TothP.P.ZhaoS.AgrawalD.K.LibbyP.ChatzizisisY.S.Pleiotropic anti-atherosclerotic effects of PCSK9 inhibitors from molecular biology to clinical translation2018202010.1007/s11883-018-0718-x29525934Search in Google Scholar
Khademi F., Momtazi-Borojeni A.A., Reiner Ž., Banach M., Al-Rasadi K.A., Sahebkar A.: PCSK9 and infection: A potentially useful or dangerous association? J. Cell. Pysiol., 2018; 233: 2920–2927KhademiF.Momtazi-BorojeniA.A.ReinerŽ.BanachM.Al-RasadiK.A.SahebkarA.PCSK9 and infection: A potentially useful or dangerous association?20182332920292710.1002/jcp.26040Search in Google Scholar
Kockx M., Kritharides L.: Pancreatic PCSK9 and its involvement in diabetes. J. Thorac. Dis., 2019; 11: S2018–S2022KockxM.KritharidesL.Pancreatic PCSK9 and its involvement in diabetes201911S2018S202210.21037/jtd.2019.06.37Search in Google Scholar
Koren M.J., Scott R., Kim J.B., Knusel B., Liu T., Lei L., Bolognese M., Wasserman S.M.: Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as mono-therapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study. Lancet, 2012; 380: 1995–2006KorenM.J.ScottR.KimJ.B.KnuselB.LiuT.LeiL.BologneseM.WassermanS.M.Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as mono-therapy in patients with hypercholesterolaemia (MENDEL): A randomised, double-blind, placebo-controlled, phase 2 study20123801995200610.1016/S0140-6736(12)61771-1Search in Google Scholar
Koskinas K.C., Windecker S., Buhayer A., Gencer B., Pedrazzini G., Mueller C., Cook S., Muller O., Matter C.M., Räber L., Heg D., Mach F.: Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. Clin. Cardiol., 2018; 41: 1513–1520KoskinasK.C.WindeckerS.BuhayerA.GencerB.PedrazziniG.MuellerC.CookS.MullerO.MatterC.M.RäberL.HegD.MachF.Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial2018411513152010.1002/clc.23112649013830421481Search in Google Scholar
Kruit J.K., Groen A.K., van Berkel T.J., Kuipers F.: Emerging roles of the intestine in control of cholesterol metabolism. World J. Gastroenterol., 2006; 12: 6429–6439KruitJ.K.GroenA.K.van BerkelT.J.KuipersF.Emerging roles of the intestine in control of cholesterol metabolism2006126429643910.3748/wjg.v12.i40.6429410063117072974Search in Google Scholar
Kühnast S., Van Der Hoorn J.W., Pieterman E.J., van den Hoek A.M., Sasiela W.J., Gusarova V., Peyman A., Schäfer H.L., Schwahn U., Jukema J.W., Princen H.M.: Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J. Lipid Res., 2014; 55: 2103–2112KühnastS.Van Der HoornJ.W.PietermanE.J.van den HoekA.M.SasielaW.J.GusarovaV.PeymanA.SchäferH.L.SchwahnU.JukemaJ.W.PrincenH.M.Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin2014552103211210.1194/jlr.M051326417400325139399Search in Google Scholar
Labonté P., Begley S., Guévin C., Asselin M.C., Nassoury N., Mayer G., Prat A., Seidah N.G.: PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology, 2009; 50: 17–24LabontéP.BegleyS.GuévinC.AsselinM.C.NassouryN.MayerG.PratA.SeidahN.G.PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression200950172410.1002/hep.2291119489072Search in Google Scholar
Leak T.S., Keene K.L., Langefeld C.D., Gallagher C.J., Mychaleckyj J.C., Freedman B.I., Bowden D.W., Rich S.S., Sale M.M.: Association of the proprotein convertase subtilisin/kexin-type 2 (PCSK2) gene with type 2 diabetes in an African American population. Mol. Genet. Metab., 2007; 92: 145–150LeakT.S.KeeneK.L.LangefeldC.D.GallagherC.J.MychaleckyjJ.C.FreedmanB.I.BowdenD.W.RichS.S.SaleM.M.Association of the proprotein convertase subtilisin/kexin-type 2 (PCSK2) gene with type 2 diabetes in an African American population20079214515010.1016/j.ymgme.2007.05.014275282417618154Search in Google Scholar
Leiva E., Wehinger S.R., Guzmán L., Orrego R.: Role of oxidized LDL in atherosclerosis. W: Hypercholesterolemia, red.: S.A. Kumar. IntechOpen Limited, London 2015, 55–77LeivaE.WehingerS.R.GuzmánL.OrregoR.Role of oxidized LDL in atherosclerosisW:red.:KumarS.A.IntechOpen LimitedLondon2015557710.5772/59375Search in Google Scholar
Leritz E.C., McGlinchey R.E., Salat D.H., Milberg W.P.: Elevated levels of serum cholesterol are associated with better performance on tasks of episodic memory. Metab. Brain Dis., 2016; 31: 465–473LeritzE.C.McGlincheyR.E.SalatD.H.MilbergW.P.Elevated levels of serum cholesterol are associated with better performance on tasks of episodic memory20163146547310.1007/s11011-016-9797-y491347426873100Search in Google Scholar
Levels J.H.M., Marquart J.A., Abraham P.R., van den Ende A.E., Molhuizen H.O.F., van Deventer S.J.H., Meijers J.C.M.: Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein. Infect. Immun., 2005; 73: 2321–2326LevelsJ.H.M.MarquartJ.A.AbrahamP.R.van den EndeA.E.MolhuizenH.O.F.van DeventerS.J.H.MeijersJ.C.M.Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein2005732321232610.1128/IAI.73.4.2321-2326.2005Search in Google Scholar
Li T., Jiang S., Ni B., Cui Q., Liu Q., Zhao H.: Discontinued drugs for the treatment of cardiovascular disease from 2016 to 2018. Int. J. Mol. Sci., 2019; 20: 4513LiT.JiangS.NiB.CuiQ.LiuQ.ZhaoH.Discontinued drugs for the treatment of cardiovascular disease from 2016 to 2018201920451310.3390/ijms20184513Search in Google Scholar
Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Backer G.G., Delgado V., Ference B.A., Graham I.M., Halliday A., Landmesser U., Mihaylova B., Pedersen T.R.: 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J., 2020; 41: 111–188MachF.BaigentC.CatapanoA.L.KoskinasK.C.CasulaM.BadimonL.ChapmanM.J.De BackerG.G.DelgadoV.FerenceB.A.GrahamI.M.HallidayA.LandmesserU.MihaylovaB.PedersenT.R.2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk20204111118810.1093/eurheartj/ehz455Search in Google Scholar
Małuch I., Walewska A., Sikorska E., Prahl A.: Konwertazy probiałkowe – rodzina proteaz serynowych o szerokim spektrum funkcji fizjologicznych. Post. Bioch., 2016; 62: 472–481MałuchI.WalewskaA.SikorskaE.PrahlA.Konwertazy probiałkowe – rodzina proteaz serynowych o szerokim spektrum funkcji fizjologicznych201662472481Search in Google Scholar
Mannarino M.R., Sahebkar A., Bianconi V., Serban M.C., Banach M., Pirro M.: PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results? J. Clin. Lipidol., 2018; 12: 1123–1132MannarinoM.R.SahebkarA.BianconiV.SerbanM.C.BanachM.PirroM.PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?2018121123113210.1016/j.jacl.2018.05.012Search in Google Scholar
Mbikay M., Mayne J., Seidah N.G., Chrétien M.: Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms. Med. Hypotheses, 2007; 69: 1010–1017MbikayM.MayneJ.SeidahN.G.ChrétienM.Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms2007691010101710.1016/j.mehy.2007.03.018Search in Google Scholar
Monami M., Sesti G., Mannucci E.: PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes. Diabetes Obes. Metab., 2019; 21: 903–908MonamiM.SestiG.MannucciE.PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes20192190390810.1111/dom.13599Search in Google Scholar
Muldoon M.F., Barger S.D., Ryan C.M., Flory J.D., Lehoczky J.P., Matthews K.A., Manuck S.B.: Effects of lovastatin on cognitive function and psychological well-being. Am. J. Med., 2000; 108: 538–546MuldoonM.F.BargerS.D.RyanC.M.FloryJ.D.LehoczkyJ.P.MatthewsK.A.ManuckS.B.Effects of lovastatin on cognitive function and psychological well-being200010853854610.1016/S0002-9343(00)00353-3Search in Google Scholar
Naureckiene S., Ma L., Sreekumar K., Purandare U., Lo C.F., Huang Y., Chiang L.W., Grenier J.M., Ozenberger B.A., Jacobsen J.S., Kennedy J.D., DiStefano P.S., Wood A., Bingham B.: Functional characterization of Narc 1, a novel proteinase related to proteinase K. Arch. Biochem. Biophys., 2003; 420: 55–67NaureckieneS.MaL.SreekumarK.PurandareU.LoC.F.HuangY.ChiangL.W.GrenierJ.M.OzenbergerB.A.JacobsenJ.S.KennedyJ.D.DiStefanoP.S.WoodA.BinghamB.Functional characterization of Narc 1, a novel proteinase related to proteinase K.2003420556710.1016/j.abb.2003.09.01114622975Search in Google Scholar
Nishikido T., Ray K.K.: Inclisiran for the treatment of dyslipidemia. Expert Opin. Investig. Drugs, 2018; 27: 287–294NishikidoT.RayK.K.Inclisiran for the treatment of dyslipidemia20182728729410.1080/13543784.2018.144243529451410Search in Google Scholar
Norata G.D., Tavori H., Pirillo A., Fazio S., Catapano A.L.: Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering. Cardiovasc. Res., 2016; 112: 429–442NorataG.D.TavoriH.PirilloA.FazioS.CatapanoA.L.Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering201611242944210.1093/cvr/cvw194503195027496869Search in Google Scholar
Okopień B., Bułdak Ł., Bołdys A.: Current and future trends in the lipid lowering therapy. Pharmacol. Rep., 2016; 68: 737–747OkopieńB.BułdakŁ.BołdysA.Current and future trends in the lipid lowering therapy20166873774710.1016/j.pharep.2016.03.01627180022Search in Google Scholar
Pasta A., Cremonini A.L., Pisciotta L., Buscaglia A., Porto I., Barra F., Ferrero S., Brunelli C., Rosa G.M.: PCSK9 inhibitors for treating hypercholesterolemia. Expert Opin. Pharmacother., 2020; 21: 353–363PastaA.CremoniniA.L.PisciottaL.BuscagliaA.PortoI.BarraF.FerreroS.BrunelliC.RosaG.M.PCSK9 inhibitors for treating hypercholesterolemia20202135336310.1080/14656566.2019.170297031893957Search in Google Scholar
Pavlakou P., Liberopoulos E., Dounousi E., Elisaf M.: PCSK9 in chronic kidney disease. Int. Urol. Nephrol., 2017; 49: 1015–1024PavlakouP.LiberopoulosE.DounousiE.ElisafM.PCSK9 in chronic kidney disease2017491015102410.1007/s11255-017-1505-228084558Search in Google Scholar
Perego C., Da Dalt L., Pirillo A., Galli A., Catapano A.L., Norata G.D.: Cholesterol metabolism, pancreatic β-cell function and diabetes. Biochim. Biophys. Acta Mol. Basis Dis., 2019; 1865: 2149–2156PeregoC.Da DaltL.PirilloA.GalliA.CatapanoA.L.NorataG.D.Cholesterol metabolism, pancreatic β-cell function and diabetes201918652149215610.1016/j.bbadis.2019.04.01231029825Search in Google Scholar
Poirier S., Mayer G., Benjannet S., Bergeron E., Marcinkiewicz J., Nassoury N., Mayer H., Nimpf J., Prat A., Seidah N.G.: The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem., 2008; 283: 2363–2372PoirierS.MayerG.BenjannetS.BergeronE.MarcinkiewiczJ.NassouryN.MayerH.NimpfJ.PratA.SeidahN.G.The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER220082832363237210.1074/jbc.M70809820018039658Search in Google Scholar
Postmus I., Trompet S., de Craen A.J., Buckley B.M., Ford I., Stott D.J., Sattar N., Slagboom P.E., Westendorp R.G., Jukema J.W.: PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population. J. Lipid Res., 2013; 54: 561–566PostmusI.TrompetS.de CraenA.J.BuckleyB.M.FordI.StottD.J.SattarN.SlagboomP.E.WestendorpR.G.JukemaJ.W.PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population20135456156610.1194/jlr.M033969Search in Google Scholar
Preiss D., Seshasai S.R., Welsh P., Murphy S.A., Ho J.E., Waters D.D., DeMicco D.A., Barter P., Cannon C.P., Sabatine M.S., Braunwald E., Kastelein J.J., de Lemos J.A., Blazing M.A., Pedersen T.R. i wsp.: Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. JAMA, 2011; 305: 2556–2564PreissD.SeshasaiS.R.WelshP.MurphyS.A.HoJ.E.WatersD.D.DeMiccoD.A.BarterP.CannonC.P.SabatineM.S.BraunwaldE.KasteleinJ.J.de LemosJ.A.BlazingM.A.PedersenT.R.i wsp.Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis20113052556256410.1001/jama.2011.86021693744Search in Google Scholar
Ramanathan A., Gusarova V., Stahl N., Gurnett-Bander A., Kyratsous C.A.: Alirocumab, a therapeutic human antibody to PCSK9, does not affect CD81 levels or hepatitis C virus entry and replication into hepatocytes. PLoS One, 2016; 11: e0154498RamanathanA.GusarovaV.StahlN.Gurnett-BanderA.KyratsousC.A.Alirocumab, a therapeutic human antibody to PCSK9, does not affect CD81 levels or hepatitis C virus entry and replication into hepatocytes201611e015449810.1371/journal.pone.0154498484599827115873Search in Google Scholar
Ramin-Mangata S., Blanchard V., Lambert G.: Key aspects of PCSK9 inhibition beyond LDL lowering. Curr. Opin. Lipidol., 2018; 29: 453–458Ramin-MangataS.BlanchardV.LambertG.Key aspects of PCSK9 inhibition beyond LDL lowering20182945345810.1097/MOL.000000000000055130199407Search in Google Scholar
Ramos-Molina B., Martin M.G., Lindberg I.: PCSK1 variants and human obesity. Prog. Mol. Biol. Transl. Sci., 2016; 140: 47–74Ramos-MolinaB.MartinM.G.LindbergI.PCSK1 variants and human obesity2016140477410.1016/bs.pmbts.2015.12.001608239027288825Search in Google Scholar
Ray K.K., Corral P., Morales E., Nicholls S.J.: Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: Current and future options. Lancet, 2019; 394: 697–708RayK.K.CorralP.MoralesE.NichollsS.J.Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: Current and future options201939469770810.1016/S0140-6736(19)31950-6Search in Google Scholar
Ricci C., Ruscica M., Camera M., Rossetti L., Macchi C., Colciago A., Zanotti I., Lupo M.G., Adorni M.P., Cicero A.F., Fogacci F., Corsini A., Ferri N.: PCSK9 induces a pro-inflammatory response in macrophages. Sci. Rep., 2018; 8: 2267RicciC.RuscicaM.CameraM.RossettiL.MacchiC.ColciagoA.ZanottiI.LupoM.G.AdorniM.P.CiceroA.F.FogacciF.CorsiniA.FerriN.PCSK9 induces a pro-inflammatory response in macrophages20188226710.1038/s41598-018-20425-xSearch in Google Scholar
Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M. Jr, Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., Nordestgaard B.G., Shepherd J., Willerson J.T., Glynn R.J., JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Eng. J. Med., 2008; 359: 2195–2207RidkerP.M.DanielsonE.FonsecaF.A.GenestJ.GottoA.M.JrKasteleinJ.J.KoenigW.LibbyP.LorenzattiA.J.MacFadyenJ.G.NordestgaardB.G.ShepherdJ.WillersonJ.T.GlynnR.J.JUPITER Study GroupRosuvastatin to prevent vascular events in men and women with elevated C-reactive protein20083592195220710.1056/NEJMoa0807646Search in Google Scholar
Ridker P.M., Tardif J.C., Amarenco P., Duggan W., Glynn R.J., Jukema J.W., Kastelein J.J., Kim A.M., Koenig W., Nissen S., Revkin J., Rose L.M., Santos R.D., Schwartz P.F. i wsp.: Lipid-reduction variability and antidrug-antibody formation with bococizumab. N. Eng. J. Med., 2017; 376: 1517–1526RidkerP.M.TardifJ.C.AmarencoP.DugganW.GlynnR.J.JukemaJ.W.KasteleinJ.J.KimA.M.KoenigW.NissenS.RevkinJ.RoseL.M.SantosR.D.SchwartzP.F.i wsp.Lipid-reduction variability and antidrug-antibody formation with bococizumab20173761517152610.1056/NEJMoa1614062Search in Google Scholar
Roth E.M., Goldberg A.C., Catapano A.L., Torri A., Yancopoulos G.D., Stahl N., Brunet A., Lecorps G., Colhoun H.M.: Antidrug antibodies in patients treated with alirocumab. N. Eng. J. Med., 2017; 376: 1589–1590RothE.M.GoldbergA.C.CatapanoA.L.TorriA.YancopoulosG.D.StahlN.BrunetA.LecorpsG.ColhounH.M.Antidrug antibodies in patients treated with alirocumab20173761589159010.1056/NEJMc1616623Search in Google Scholar
Rouillé Y., Martin S., Steiner D.F.: Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide. J. Biol. Chem., 1995; 270: 26488–26496RouilléY.MartinS.SteinerD.F.Differential processing of proglucagon by the subtilisin-like prohormone convertases PC2 and PC3 to generate either glucagon or glucagon-like peptide1995270264882649610.1074/jbc.270.44.26488Search in Google Scholar
Ruscica M., Ricci C., Macchi C., Magni P., Cristofani R., Liu J., Corsini A., Ferri N.: Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J. Biol. Chem, 2016; 291: 3508–3519RuscicaM.RicciC.MacchiC.MagniP.CristofaniR.LiuJ.CorsiniA.FerriN.Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line20162913508351910.1074/jbc.M115.664706Search in Google Scholar
Sabatine M.S.: PCSK9 inhibitors: Clinical evidence and implementation. Nat. Rev. Cardiol., 2019; 16: 155–165SabatineM.S.PCSK9 inhibitors: Clinical evidence and implementation20191615516510.1038/s41569-018-0107-8Search in Google Scholar
Sabatine M.S., Giugliano R.P., Keech A.C., Honarpour N., Wiviott S.D., Murphy S.A., Kuder J.F., Wang H., Liu T., Wasserman S.M., Sever P.S., Pedersen T.R., FOURIER Steering Committee and Investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Eng. J. Med., 2017; 376: 1713–1722SabatineM.S.GiuglianoR.P.KeechA.C.HonarpourN.WiviottS.D.MurphyS.A.KuderJ.F.WangH.LiuT.WassermanS.M.SeverP.S.PedersenT.R.FOURIER Steering Committee and InvestigatorsEvolocumab and clinical outcomes in patients with cardiovascular disease20173761713172210.1056/NEJMoa1615664Search in Google Scholar
Sattar N., Preiss D., Murray H.M., Welsh P., Buckley B.M., de Craen A.J., Seshasai S.R., McMurray J.J., Freeman D.J., Jukema J.W., Macfarlane P.W., Packard C.J., Stott D.J., Westendorp R.G., Shepherd J.: Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet, 2010; 375: 735–742SattarN.PreissD.MurrayH.M.WelshP.BuckleyB.M.de CraenA.J.SeshasaiS.R.McMurrayJ.J.FreemanD.J.JukemaJ.W.MacfarlaneP.W.PackardC.J.StottD.J.WestendorpR.G.ShepherdJ.Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials201037573574210.1016/S0140-6736(09)61965-6Search in Google Scholar
Scamuffa N., Calvo F., Chrétien M., Seidah N.G., Khatib A.M.: Proprotein convertases: Lessons from knockouts. FASEB J., 2006; 20: 1954–1963ScamuffaN.CalvoF.ChrétienM.SeidahN.G.KhatibA.M.Proprotein convertases: Lessons from knockouts2006201954196310.1096/fj.05-5491revSearch in Google Scholar
Schmidt A.F., Swerdlow D.I., Holmes M.V., Patel R.S., Fairhurst-Hunter Z., Lyall D.M., Hartwig F.P., Horta B.L., Hyppönen E., Power C., Moldovan M., van Iperen E., Hovingh G.K., Demuth I., Norman K.: PCSK9 genetic variants and risk of type 2 diabetes: A mendelian randomisation study. Lancet Diabetes Endocrinol., 2017; 5: 97–105SchmidtA.F.SwerdlowD.I.HolmesM.V.PatelR.S.Fairhurst-HunterZ.LyallD.M.HartwigF.P.HortaB.L.HyppönenE.PowerC.MoldovanM.van IperenE.HovinghG.K.DemuthI.NormanK.PCSK9 genetic variants and risk of type 2 diabetes: A mendelian randomisation study201759710510.1016/S2213-8587(16)30396-5Search in Google Scholar
Schmidt R.J., Beyer T.P., Bensch W.R., Qian Y.W., Lin A., Kowala M., Alborn W.E., Konrad R.J., Cao G.: Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem. Biophys. Res. Commun., 2008; 370: 634–640SchmidtR.J.BeyerT.P.BenschW.R.QianY.W.LinA.KowalaM.AlbornW.E.KonradR.J.CaoG.Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo200837063464010.1016/j.bbrc.2008.04.00418406350Search in Google Scholar
Schwartz G.G., Steg P.G., Szarek M., Bhatt D.L., Bittner V.A., Diaz R., Edelberg J.M., Goodman S.G., Hanotin C., Harrington R.A., Jukema J.W., Lecorps G., Mahaffey K.W., Moryusef A., Pordy R., Quintero K., Roe M.T.: Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Eng. J. Med., 2018; 379: 2097–2107SchwartzG.G.StegP.G.SzarekM.BhattD.L.BittnerV.A.DiazR.EdelbergJ.M.GoodmanS.G.HanotinC.HarringtonR.A.JukemaJ.W.LecorpsG.MahaffeyK.W.MoryusefA.PordyR.QuinteroK.RoeM.T.Alirocumab and cardiovascular outcomes after acute coronary syndrome20183792097210710.1056/NEJMoa180117430403574Search in Google Scholar
Seidah N.G.: PCSK9 as a therapeutic target of dyslipidemia. Expert Opin. Ther. Targets, 2009; 13: 19–28SeidahN.G.PCSK9 as a therapeutic target of dyslipidemia200913192810.1517/1472822080260071519063703Search in Google Scholar
Seidah N.G.: The proprotein convertases, 20 years later. Methods Mol. Biol., 2011; 768: 23–57SeidahN.G.The proprotein convertases, 20 years later2011768235710.1007/978-1-61779-204-5_321805237Search in Google Scholar
Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B., Stifani S., Basak A., Prat A., Chretien M.: The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U. S. A., 2003; 100: 928–933SeidahN.G.BenjannetS.WickhamL.MarcinkiewiczJ.JasminS.B.StifaniS.BasakA.PratA.ChretienM.The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation200310092893310.1073/pnas.033550710029870312552133Search in Google Scholar
Seidah N.G., Hamelin J., Mamarbachi M., Dong W., Tardos H., Mbikay M., Chretien M., Day R.: cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases. Proc. Natl. Acad. Sci. U. S. A., 1996; 93: 3388–3393SeidahN.G.HamelinJ.MamarbachiM.DongW.TardosH.MbikayM.ChretienM.DayR.cDNA structure, tissue distribution, and chromosomal localization of rat PC7, a novel mammalian proprotein convertase closest to yeast kexin-like proteinases1996933388339310.1073/pnas.93.8.3388396188622945Search in Google Scholar
Seidah N.G., Prat A.: The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov., 2012; 11: 367–383SeidahN.G.PratA.The biology and therapeutic targeting of the proprotein convertases20121136738310.1038/nrd369922679642Search in Google Scholar
Sharotri V., Collier D.M., Olson D.R., Zhou R., Snyder P.M.: Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J. Biol. Chem., 2012; 287: 19266–19274SharotriV.CollierD.M.OlsonD.R.ZhouR.SnyderP.M.Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9)2012287192661927410.1074/jbc.M112.363382336595822493497Search in Google Scholar
Shrestha P., van de Sluis B., Dullaart R.P.F., van den Born J.: Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cell. Signal., 2019; 55: 53–64ShresthaP.van de SluisB.DullaartR.P.F.van den BornJ.Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia201955536410.1016/j.cellsig.2018.12.001Search in Google Scholar
Steffens D., Bramlage P., Scheeff C., Kasner M., Hassanein A., Friebel J., Rauch-Kröhnert U.: PCSK9 inhibitors and cardiovascular outcomes. Expert Opin. Biol. Ther., 2020; 20: 35–47SteffensD.BramlageP.ScheeffC.KasnerM.HassaneinA.FriebelJ.Rauch-KröhnertU.PCSK9 inhibitors and cardiovascular outcomes202020354710.1080/14712598.2020.1677604Search in Google Scholar
Suchy D., Łabuzek K., Stadnicki A., Okopień B.: Ezetimibe – a new approach in hypercholesterolemia management. Pharmacol. Rep., 2011; 63: 1335–1348SuchyD.ŁabuzekK.StadnickiA.OkopieńB.Ezetimibe – a new approach in hypercholesterolemia management2011631335134810.1016/S1734-1140(11)70698-3Search in Google Scholar
Syed G.H., Tang H., Khan M., Hassanein T., Liu J., Siddiqui A.: Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J. Virol., 2014; 88: 2519–2529SyedG.H.TangH.KhanM.HassaneinT.LiuJ.SiddiquiA.Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation2014882519252910.1128/JVI.02727-13Search in Google Scholar
Tadros H., Chrétien M., Mbikay M.: The testicular germ-cell pro-tease PC4 is also expressed in macrophage-like cells of the ovary. J. Reprod. Immunol., 2001; 49: 133–152TadrosH.ChrétienM.MbikayM.The testicular germ-cell pro-tease PC4 is also expressed in macrophage-like cells of the ovary20014913315210.1016/S0165-0378(00)00085-1Search in Google Scholar
Tang Z.H., Peng J., Ren Z., Yang J., Li T.T., Li T.H., Wang Z., Wei D.H., Liu L.S., Zheng X.L., Jiang Z.S.: New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway. Atherosclerosis, 2017; 262: 113–122TangZ.H.PengJ.RenZ.YangJ.LiT.T.LiT.H.WangZ.WeiD.H.LiuL.S.ZhengX.L.JiangZ.S.New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway201726211312210.1016/j.atherosclerosis.2017.04.02328535426Search in Google Scholar
Taskinen M.R., Björnson E., Andersson L., Kahri J., Porthan K., Matikainen N., Söderlund S., Pietiläinen K., Hakkarainen A., Lund-bom N., Nilsson R., Ståhlman M., Adiels M., Parini P., Packard C.: Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipo-proteins in type II diabetic subjects. J. Clin. Lipidol., 2020; 14: 77–87TaskinenM.R.BjörnsonE.AnderssonL.KahriJ.PorthanK.MatikainenN.SöderlundS.PietiläinenK.HakkarainenA.Lund-bomN.NilssonR.StåhlmanM.AdielsM.PariniP.PackardC.Impact of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab on the postprandial responses of triglyceride-rich lipo-proteins in type II diabetic subjects202014778710.1016/j.jacl.2019.12.00331917184Search in Google Scholar
Tavori H., Giunzioni I., Predazzi I.M., Plubell D., Shivinsky A., Miles J., Devay R.M., Liang H., Rashid S., Linton M.F., Fazio S.: Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms. Cardiovasc. Res., 2016, 110: 268–278TavoriH.GiunzioniI.PredazziI.M.PlubellD.ShivinskyA.MilesJ.DevayR.M.LiangH.RashidS.LintonM.F.FazioS.Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms201611026827810.1093/cvr/cvw053483663126980204Search in Google Scholar
Thomas G.: Furin at the cutting edge: From protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol., 2002; 3: 753–766ThomasG.Furin at the cutting edge: From protein traffic to embryogenesis and disease2002375376610.1038/nrm934196475412360192Search in Google Scholar
Van Bruggen F.H., Nijhuis G.B.J., Zuidema S.U., Luijendijk H.: Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: A systematic review. Expert Rev. Clin. Pharmacol., 2020; 13: 787–796Van BruggenF.H.NijhuisG.B.J.ZuidemaS.U.LuijendijkH.Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: A systematic review20201378779610.1080/17512433.2020.178783232597252Search in Google Scholar
Walley K.R., Thain K.R., Russell J.A., Reilly M.P., Meyer N.J., Ferguson J.F., Christie J.D., Nakada T.A., Fjell C.D., Thair S.A., Cirstea M.S., Boyd J.H.: PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci. Transl. Med., 2014; 6: 258ra143WalleyK.R.ThainK.R.RussellJ.A.ReillyM.P.MeyerN.J.FergusonJ.F.ChristieJ.D.NakadaT.A.FjellC.D.ThairS.A.CirsteaM.S.BoydJ.H.PCSK9 is a critical regulator of the innate immune response and septic shock outcome20146258ra14310.1126/scitranslmed.3008782434214725320235Search in Google Scholar
Williams D.M., Finan C., Schmidt A.F., Burgess S., Hingorani A.D.: Lipid lowering and Alzheimer disease risk: A Mendelian randomization study. Ann. Neurol., 2020, 87: 30–39WilliamsD.M.FinanC.SchmidtA.F.BurgessS.HingoraniA.D.Lipid lowering and Alzheimer disease risk: A Mendelian randomization study202087303910.1002/ana.25642694451031714636Search in Google Scholar
Wu C.Y., Tang Z.H., Jiang L., Li X.F., Jiang Z.S., Liu L.S.: PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol. Cell. Biochem., 2012, 359: 347–358WuC.Y.TangZ.H.JiangL.LiX.F.JiangZ.S.LiuL.S.PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway201235934735810.1007/s11010-011-1028-621847580Search in Google Scholar
Yano H., Horinaka S., Ishimitsu T.: Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J. Cardiol., 2020; 75: 289–295YanoH.HorinakaS.IshimitsuT.Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome20207528929510.1016/j.jjcc.2019.08.00231495548Search in Google Scholar
Yurtseven E., Ural D., Baysal K., Tokgözoğlu L.: An update on the role of PCSK9 in atherosclerosis. J. Atheroscler. Thromb., 2020; 27: 909–918YurtsevenE.UralD.BaysalK.TokgözoğluL.An update on the role of PCSK9 in atherosclerosis20202790991810.5551/jat.55400750872132713931Search in Google Scholar
Zheng-Lin B., Ortiz A.: Lipid management in chronic kidney disease: Systematic review of PCSK9 targeting. Drugs, 2018; 78: 215–229Zheng-LinB.OrtizA.Lipid management in chronic kidney disease: Systematic review of PCSK9 targeting20187821522910.1007/s40265-017-0858-229299849Search in Google Scholar
Zimetti F., Caffarra P., Ronda N., Favari E., Adorni M.P., Zanotti I., Bernini F., Barocco F., Spallazzi M., Galimberti D., Ricci C., Ruscica M., Corsini A., Ferri N.: Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s disease. J. Alzheimers Dis., 2017; 55: 315–320ZimettiF.CaffarraP.RondaN.FavariE.AdorniM.P.ZanottiI.BerniniF.BaroccoF.SpallazziM.GalimbertiD.RicciC.RuscicaM.CorsiniA.FerriN.Increased PCSK9 cerebrospinal fluid concentrations in Alzheimer’s disease20175531532010.3233/JAD-16041127662294Search in Google Scholar